Implantable Remote Patient Monitoring Devices Market Report 2025

The implantable remote patient monitoring devices market size has grown exponentially in recent years. It will grow from $8.39 billion in 2024 to $10.26 billion in 2025 at a compound annual growth rate (CAGR) of 22.2%. The growth observed during the historic period can be linked to the increasing prevalence of chronic and cardiovascular diseases, the rising demand for early diagnosis and continuous monitoring, the expanding aging population in need of long-term care, the shift toward home-based healthcare, and escalating healthcare costs that emphasize the importance of preventive monitoring.

The implantable remote patient monitoring devices market size is expected to see exponential growth in the next few years. It will grow to $22.59 billion in 2029 at a compound annual growth rate (CAGR) of 21.8%. The forecast period’s growth is expected to be driven by increased government support and reimbursement policies, rising awareness of personalized and precision medicine, greater investments in digital health and MedTech startups, and a higher incidence of post-surgical complications and rehospitalizations. Key trends include advancements in miniaturization and biocompatible materials, the use of artificial intelligence (AI) and machine learning for predictive analytics, integration with 5G and Internet of Things (IoT) networks, the emergence of battery-free and energy-harvesting implants, and improved cybersecurity protocols for medical implants.

The growing adoption of telehealth services is anticipated to drive the expansion of the implantable remote patient monitoring devices market in the coming years. Telehealth refers to healthcare services delivered remotely through phones, video consultations, or apps, enabling patients to consult with doctors without physically visiting clinics or hospitals. This rising adoption is largely due to the increasing need for continuous and real-time health monitoring among patients with chronic diseases, as it allows for timely medical interventions without frequent hospital visits. By enabling real-time data transmission between patients and healthcare providers, telehealth enhances the effectiveness of implantable remote patient monitoring devices, supporting faster medical decision-making and reducing the necessity of in-person appointments. This approach improves chronic disease management by facilitating early interventions, boosting healthcare efficiency, and offering greater convenience to patients. For example, in May 2024, the Australian Digital Health Agency reported that between March 2020 and July 2022, more than 95,000 practitioners had used telehealth services, delivering 118.2 million telehealth consultations to 18 million patients. As a result, the increasing adoption of telehealth services is fueling the growth of the implantable remote patient monitoring devices market.

Leading companies in the implantable remote patient monitoring devices sector are developing innovative solutions such as implantable cardiac monitors to improve the accuracy of arrhythmia monitoring. An implantable cardiac monitor (ICM), also known as an implantable loop recorder (ILR), is a small device placed just under the skin, usually on the left side of the chest, that continuously records the heart’s electrical activity over long periods. For instance, in June 2023, Biotronik AG, a Switzerland-based medical technology company, introduced the BIOMONITOR IV implantable cardiac monitor. This advanced ICM integrates BIOTRONIK’s SmartECG technology with artificial intelligence, cutting false positive detections by 86% while maintaining 98% accuracy for true episodes. Additionally, it can differentiate between premature atrial contractions (PACs) and premature ventricular contractions (PVCs), equipping healthcare providers with improved tools for diagnosis and risk assessment.

In December 2022, Johnson & Johnson, a US-based pharmaceutical company, acquired Abiomed Inc. for approximately \$16.6 billion. This acquisition strengthens Johnson & Johnson’s MedTech portfolio by giving the company a foothold in the heart recovery market through Abiomed’s implantable Impella heart pumps, which are used in cases of acute heart failure and high-risk PCI procedures. Abiomed Inc., a leading US-based medical device technology firm, contributes to the implantable remote patient monitoring sector with its advanced heart pump solutions.

Major players in the implantable remote patient monitoring devices market are Abbott Laboratories, Honeywell Life Sciences, Medtronic plc, Siemens Healthineers, Philips Healthcare, GE HealthCare Technologies Inc., Boston Scientific Corporation, Dexcom Inc., Zoll Medical Corporation, Nihon Kohden Corporation, LivaNova PLC, MicroPort Scientific Corporation, iRhythm Technologies Inc., NeuroPace Inc., Profusa Inc., Senseonics Holdings Inc., Xeltis AG, GlySens Inc., Kenzen Inc., Qura Inc.

North America was the largest region in the implantable remote patient monitoring devices market in 2024. The regions covered in implantable remote patient monitoring devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the implantable remote patient monitoring devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Implantable remote patient monitoring devices are medical technologies surgically inserted into a patient’s body to continuously measure physiological parameters such as heart rhythm, blood pressure, and glucose levels. These devices feature built-in sensors and wireless communication capabilities, allowing them to capture real-time health data and transmit it to healthcare professionals. This facilitates ongoing monitoring, early detection of potential health problems, and prompt medical intervention, while also reducing the need for frequent hospital visits.

The key product categories of implantable remote patient monitoring devices include blood glucose monitoring systems, cardiac monitoring devices, weight monitoring devices, and others. They are utilized in the management of cardiovascular diseases, neurological disorders, diabetes, and various other conditions, serving end users such as hospitals, ambulatory surgical centers, home care environments, and beyond.

The implantable remote patient monitoring devices market research report is one of a series of new reports that provides implantable remote patient monitoring devices market statistics, including implantable remote patient monitoring devices industry global market size, regional shares, competitors with a implantable remote patient monitoring devices market share, detailed implantable remote patient monitoring devices market segments, market trends and opportunities, and any further data you may need to thrive in the implantable remote patient monitoring devices industry. This implantable remote patient monitoring devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The implantable remote patient monitoring devices market consists of revenues earned by entities by providing services such as continuous health monitoring, early detection of health problems, remote data transmission, real-time alerts and reduced hospital visits. The market value includes the value of related goods sold by the service provider or included within the service offering. The implantable remote patient monitoring devices market also includes sales of implantable hemodynamic monitors, implantable pulmonary artery pressure sensors, insertable loop recorders (ILRs), subcutaneous electrocardiogram (ECG) monitors, and long-term heart rhythm monitoring devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.